Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2006

View Archived Issues

Lasofoxifene improves bone parameters in postmenopausal women

Phase I study finds intraputaminal CERE-120 feasible in Parkinson's disease

Anticancer activity of tetrathiomolybdate assessed in preclinical studies

Motexafin-rituximab combination shows promise in B-cell lymphoma cells

New evidence that the ERK-Kv4.2 signaling pathway represents a target for pain

Novel cardenolide UNBS-1450 active in cancer models

Docetaxel nanoparticle-aptamer bioconjugate effective in prostate cancer model

Single confirmatory phase III study planned for MC-1

Phase III study begins for DN-101 in advanced prostate cancer

Organon and Radboud University to target gene involved in tumor growth

Array achieves research milestone in Genentech collaboration

Enrollment completed in Entereg phase III program

New phase I study investigates MEDI-545 for lupus

Positive phase II findings for Ardana's testosterone cream

Raloxifene effective as tamoxifen in preventing invasive breast cancer

New compounds to target specific adenosine receptor subtypes presented

Nexavar receives European orphan medicinal product status for liver cancer

Saforis NDA filed for oral mucositis

Recent patents report new treatment strategies for respiratory diseases

New therapeutic agents for psychological disorders disclosed

New antiviral and antimycobacterial agents described in recent patents

Major component of green tea may be useful in ocular diseases

Targeting the mTOR pathway -- a promising therapeutic approach in polycystic kidney disease

Spotlight on chemokine CXCR4 receptors and cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...